Milan, Italy

Pier Giuseppe Pelicci

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2024-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Pier Giuseppe Pelicci: Innovator in Cancer Treatment

Introduction

Pier Giuseppe Pelicci is a notable inventor based in Milan, Italy. He has made significant contributions to the field of cancer treatment through his innovative research and patented methodologies. His work focuses on the development of combinational therapies that enhance the effectiveness of cancer treatments.

Latest Patents

Pier Giuseppe Pelicci holds a patent for the "Use of a combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer." This patent outlines methods for treating cancer, including those resistant to LSD1 inhibitors. The approach involves administering an effective amount of a cell cycle inhibitor, such as a CDK4/6 inhibitor or a p21 enhancer, alongside an LSD1 inhibitor. This innovative therapy aims to improve outcomes for patients suffering from various forms of cancer.

Career Highlights

Throughout his career, Pelicci has been associated with prominent institutions such as the Istituto Europeo di Oncologia and the Università degli Studi di Milano. His work in these organizations has allowed him to advance cancer research and develop new therapeutic strategies.

Collaborations

Pier Giuseppe Pelicci has collaborated with esteemed colleagues, including Saverio Minucci and Seyed Amir Hosseini. These partnerships have contributed to the advancement of cancer treatment methodologies and have fostered a collaborative research environment.

Conclusion

Pier Giuseppe Pelicci's innovative work in cancer treatment exemplifies the impact of research and invention in the medical field. His patented methodologies offer hope for improved cancer therapies and highlight the importance of collaboration in scientific advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…